BCM
NVAX icon

Bridgeway Capital Management’s Novavax NVAX Stock Holding History

Bridgeway Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-54,000
Closed -$733K – 1372
2020
Q1 		$733K Hold
54,000
– – 0.02% 648
2019
Q4 		$215K Buy
+54,000
New +$234K ﹤0.01% 1189

Other funds holding NVAX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bridgeway Capital Management's NVAX Position: Q2 2020 in Review

Bridgeway Capital Management sold out of Novavax (NVAX) in Q2 2020, closing a stake of 54,000 shares — an estimated $733K sold.

Bridgeway Capital Management first reported a position in NVAX in Q4 2019 and held it in 2 quarters. The position peaked at $733K in Q1 2020. 213 funds tracked by Wall St. Rank hold NVAX as of Q2 2020.

  • Bridgeway Capital Management reported no remaining Novavax position as of Q2 2020 after selling out during the quarter.
  • Bridgeway Capital Management sold 54,000 Novavax shares in Q2 2020, an estimated $733K.
  • Bridgeway Capital Management first reported a position in Novavax in Q4 2019 and held it in 2 quarters.
  • Bridgeway Capital Management's Novavax position peaked at $733K in Q1 2020.
  • 213 funds tracked by Wall St. Rank held Novavax as of Q2 2020.

Based on Bridgeway Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.